Jeff Caravella

Jeff Caravella joined Abiomed in January 2025 as chief financial officer after serving as vice president of business development at Johnson & Johnson’s Innovative Medicine business.

Before rejoining Johnson & Johnson in 2024, he held finance leadership roles in start-up and entrepreneurial environments, including as chief financial officer at Biotheryx, where he provided strategic leadership on the company’s financing plans, long-range financial planning initiatives and business development efforts. He also worked at Tango Therapeutics, where, as vice president of finance, he supported the design and execution of the company’s financial and corporate strategy and was responsible for building out the finance function to support its growth and initial public offering. Previously, he held senior financial roles at Editas Medicine and Charles River Laboratories.

During his prior 10-year tenure at Johnson & Johnson, he worked in various finance roles across the Pharmaceutical, Medtech and consumer sectors, supporting Licensing and Acquisitions as well as Commercial Finance.

Jeff earned his M.B.A. and B.S. from Syracuse University.